Momelotinib Hits the Mark for Deadly Bone Marrow Cancer
The investigational drug has shown benefits in myelofibrosis in a new phase 3 trial with a new sponsor, which plans to apply for FDA approval.
Medscape Medical News
source https://www.medscape.com/viewarticle/975651?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/975651?src=rss
Comments
Post a Comment